Recent epidemiological and genetic research spearheaded by scientists at the Seaver Autism Center for Research and Treatment at the Icahn School of Medicine at Mount Sinai has fundamentally shifted the medical community’s understanding of Phelan-McDermid syndrome (PMS). Published in the peer-reviewed journal Autism Research, the landmark study indicates that PMS may affect approximately 1 in every 7,300 individuals. This staggering figure is a massive upward revision from historical estimates, suggesting that tens of thousands of people are currently walking through life undiagnosed. With precision medicine and targeted clinical trials finally on the horizon, public health advocates, genetic counselors, and pharmaceutical developers are sounding the alarm: identifying these hidden patients is no longer just an academic exercise—it is an urgent medical and ethical necessity.
Phelan-McDermid syndrome is a rare genetic disorder typically triggered by a chromosomal deletion or a disruptive mutation involving the SHANK3 gene located on the long arm of chromosome 22 (specifically 22q13.33). The SHANK3 gene plays a monumental role in neurodevelopment, encoding a master scaffold protein that is critical for the formation, maturation, and function of synapses—the junctions through which neurons communicate with one another. When this gene is compromised, the synaptic architecture breaks down, leading to a broad, complex spectrum of medical, intellectual, and behavioral challenges. Affected individuals often experience global developmental delays, severe speech impairments, hypotonia (low muscle tone), motor dysfunctions, epilepsy, and gastrointestinal issues. Furthermore, the vast majority of individuals diagnosed with PMS also meet the clinical criteria for autism spectrum disorder (ASD). In fact, geneticists estimate that alterations affecting the SHANK3 gene alone account for roughly one percent of all global ASD cases.
To arrive at their groundbreaking prevalence estimates, researchers at Mount Sinai embarked on a massive, multi-institutional data-synthesis project. Recognizing that rare genetic disorders are chronically underreported due to diagnostic bottlenecks, the research team partnered with major commercial genetic testing laboratories, prestigious academic medical centers, and prominent autism research repositories. By casting a wide net across the medical landscape, the investigators analyzed genetic testing data drawn from nearly 180,000 individuals who had been diagnosed with autism and subsequently undergone comprehensive genetic evaluations.
The resulting dataset integrated information from ten separate, highly diverse sources. These included commercial powerhouses and diagnostic leaders such as GeneDx, Labcorp, and Ambry Genetics, alongside large-scale genomic research initiatives like the SPARK (Simons Foundation Powering Autism Research for Knowledge) study and the Autism Sequencing Consortium. Additionally, data from several major tertiary children’s hospitals were incorporated to capture clinical presentations across different demographics.
To bridge the gap between raw data and true population prevalence, the Mount Sinai researchers deployed sophisticated epidemiological modeling. They systematically accounted for undiagnosed individuals who lack access to specialized care, the inherent technological limitations of older or targeted genetic testing panels, and a subset of PMS patients who present with severe developmental or neurological symptoms but do not strictly meet the formal diagnostic criteria for autism spectrum disorder. Through this meticulous filtering and adjustment process, the team calculated a true prevalence rate of 13.7 cases per 100,000 individuals—translating directly to a ratio of 1 in 7,300.
When projected against broader demographic numbers, this prevalence rate implies that upward of 45,000 individuals in the United States alone could be living with Phelan-McDermid syndrome. Globally, the total number of affected individuals is likely in the hundreds of thousands, vastly outstripping earlier epidemiological models that treated the condition as an extreme medical rarity.
The persistence of such a vast diagnostic gap has confounded clinicians for years, but experts point to systemic healthcare hurdles as the primary culprit. Tess Levy, MSc, an Assistant Professor of Psychiatry at the Icahn School of Medicine at Mount Sinai, a certified genetic counselor at the Seaver Autism Center, and the first author of the published study, elaborated on these structural barriers. "The large gap between known and estimated cases is likely due in large part to the fact that many individuals with developmental disabilities and autism are never offered genetic testing," Levy explained. "Families may also face persistent insurance barriers or may receive tests that do not adequately evaluate the SHANK3 gene."
Many standard clinical evaluations stop at a behavioral diagnosis of autism without exploring the underlying molecular etiology. Without a genetic test specifically designed to detect chromosomal microdeletions or point mutations on chromosome 22, families are left in the dark regarding the root cause of their child’s condition.
The publication of this study arrives at a crucial chronological juncture for rare disease research and neurodevelopmental therapeutics. For decades, a diagnosis of Phelan-McDermid syndrome offered little more than an explanation for a patient’s symptoms, providing precious little in terms of actionable medical interventions. Families received prognostic information and supportive therapies—such as physical, occupational, and speech therapy—but could do little to alter the underlying trajectory of the disease.
However, the rapid maturation of molecular biology and precision medicine over the past ten years has dramatically altered this landscape. Today, several clinical trials are actively underway, deploying innovative precision medicine therapeutics specifically designed to target the molecular pathways disrupted by SHANK3 deficiency. These treatments aim to restore synaptic function, improve neurochemical signaling, and potentially reverse or ameliorate some of the most disabling symptoms associated with the syndrome.
This shifting paradigm transforms the value proposition of a genetic diagnosis. For families navigating the complexities of PMS, a confirmed genetic finding is no longer merely an intellectual exercise or a box checked on a medical chart. It serves as a vital gateway to specialized medical subspecialties, targeted clinical trials, robust patient support networks, and access to emerging disease-modifying drugs that could fundamentally improve a patient’s quality of life.
Recognizing the life-changing potential of these upcoming therapeutics, leadership at the Seaver Autism Center is calling for an immediate overhaul of standard pediatric neurological evaluations. Joseph D. Buxbaum, PhD, Director of the Seaver Autism Center, co-founder of the Autism Sequencing Consortium, and senior author of the study, emphasized the urgent need for universal screening. "We recommend that every child with autism undergo genetic testing, because knowledge is power," Dr. Buxbaum stated. "These genetic findings allow researchers to design more targeted clinical trials for potential therapies. I truly believe that within the next five years, we’ll see successful examples of new treatments coming from these genetic discoveries."
This comprehensive epidemiological endeavor was made possible through the collaborative financial and institutional support of CureSHANK and Neuren Pharmaceuticals—two organizations heavily invested in translating genetic discoveries into real-world clinical solutions.
The corporate and advocacy sectors have equally voiced strong support for the study’s findings, viewing them as a clarion call for reform within the biopharmaceutical and clinical communities. Dr. Rachel Groth, Head of External Innovation and Patient Advocacy at Neuren Pharmaceuticals, highlighted the ethical imperative driving these research initiatives. "Neuren Pharmaceuticals initiated this landmark PMS prevalence study in collaboration with the Seaver Autism Center at Mount Sinai and CureSHANK because, with new treatments moving closer to reality, identifying these individuals has become an ethical imperative," Dr. Groth noted. "Patients cannot benefit from these advances if they never receive a diagnosis."
Echoing this sentiment, Geraldine Bliss, Board Chair of CureSHANK, underscored the validation the study provides to families who have spent years advocating within a fractured medical system. "This study confirms what many families, clinicians, and advocates have suspected for years," Bliss remarked. "There are likely tens of thousands of individuals with Phelan-McDermid syndrome who have never received a genetic diagnosis. At a time when multiple therapeutics are advancing into clinical trials, finding these individuals has never been more important."
The empirical results of the Mount Sinai study serve to reinforce CureSHANK’s ongoing advocacy initiatives, most notably their push to expand universal access to genetic testing. These efforts align closely with the goals of Start Genetic, a prominent global awareness campaign designed to encourage patients, families, healthcare providers, and advocacy groups to adopt a "think genetic first" philosophy when evaluating developmental delays and autism spectrum disorders.
The broader socioeconomic and public health implications of this research are profound. As the healthcare sector moves steadily into an era defined by personalized medicine, the traditional "one-size-fits-all" approach to neurodevelopmental disorders is rapidly becoming obsolete. Precision treatments require precise diagnoses. By uncovering the true prevalence of Phelan-McDermid syndrome, researchers have illuminated a massive, underserved patient population that stands to benefit immensely from upcoming therapeutic breakthroughs.
Ultimately, the message emerging from the Seaver Autism Center is clear: while scientific innovation continues to forge new pathways toward effective treatments, these advances remain powerless if they cannot reach the patients who need them most. Ensuring that every child presenting with autism or unexplained developmental delays receives comprehensive, barrier-free genetic testing is the essential first step in closing the gap between medical discovery and patient care.
